Biological Age Testing: What Epigenetic Clocks Reveal in Your Blood

Your passport says you are 47. Your epigenetic clock may disagree, and according to a growing body of research, the clock wins when it comes to predicting disease risk, functional decline, and lifespan. Biological age testing using DNA methylation patterns from a blood sample has moved from academic curiosity to an accessible tool, with several services now available to Australians who want to quantify their rate of ageing rather than simply note the passage of calendar years.

This guide explains what epigenetic clocks measure, how the major algorithms differ, how they relate to other blood-based ageing markers, what the current limitations are, and what evidence-based steps can shift the trajectory.

What Is Biological Age and Why Does It Differ From Chronological Age?

Chronological age, the number of years since birth, is a blunt instrument. Two people born in the same year can have meaningfully different functional capacity, disease risk, and cellular health. Biological age attempts to quantify this internal divergence: how old your cells and tissues actually are, independent of the calendar.

The most robust current method for estimating biological age uses DNA methylation, chemical marks (methyl groups) that attach to cytosine bases throughout the genome, altering gene expression without changing the underlying DNA sequence. Methylation patterns change in predictable ways across the lifespan. Certain sites gain methylation with age; others lose it. By measuring hundreds or thousands of these sites simultaneously from a blood sample, machine-learning models can estimate a person's biological age with high accuracy.

These models are called epigenetic clocks, and the best of them don't just estimate age, they predict how quickly a person is ageing right now, and how much biological wear has accumulated relative to peers of the same chronological age.

The Major Epigenetic Clocks

Not all clocks are built the same way or ask the same question. Understanding the differences matters when interpreting results.

Horvath Clock (2013)

Steve Horvath's first-generation clock, published in 2013, analysed 353 CpG methylation sites across multiple tissue types and demonstrated it could estimate chronological age with remarkable accuracy, a mean absolute error of roughly 3.6 years across diverse tissue samples. It was a proof of concept: the methylome encodes age information that can be read out.

The limitation is that the Horvath clock was trained to estimate chronological age, not health outcomes. A person with cancer or accelerated metabolic ageing might show the same clock age as a perfectly healthy peer. It tells you how old your DNA looks, not how fast you are deteriorating.

PhenoAge (Levine, 2018)

Morgan Levine and colleagues took a different approach. Rather than training on chronological age, they first built a composite measure of phenotypic age from nine clinical blood biomarkers (including albumin, creatinine, C-reactive protein, and white cell count) that predicted 10-year mortality. They then trained a DNA methylation clock to predict this composite phenotypic age score.

The result was PhenoAge: an epigenetic clock that correlates with biological deterioration rather than just calendar time. Individuals whose PhenoAge exceeds their chronological age show elevated risk of cancer, cardiovascular disease, disability, and all-cause mortality. Importantly, PhenoAge responds to lifestyle interventions, studies have observed decreases in PhenoAge acceleration following dietary and exercise changes, making it potentially useful as a feedback tool. The foundational paper, An epigenetic biomarker of aging for lifespan and healthspan, established PhenoAge as a validated clinical ageing measure.

GrimAge (Lu et al., 2019)

GrimAge is currently considered the strongest mortality predictor among the epigenetic clocks. Rather than being trained on a composite score, GrimAge was built by training DNA methylation to predict plasma levels of proteins associated with ageing and disease (including GDF-15, cystatin C, and adrenomedullin) along with smoking pack-years. The final output incorporates both estimated protein levels and a DNAm-based smoking surrogate.

In independent validation studies, GrimAge acceleration outperforms all predecessor clocks in predicting time to death, cardiovascular disease, and physical disability. A key analysis found that GrimAge outperforms other epigenetic clocks in predicting age-related clinical phenotypes and all-cause mortality, with each year of GrimAge acceleration associated with a measurable increase in mortality risk.

For context on the metabolic and inflammatory markers that partly underlie GrimAge components, see the CRP inflammation guide and optimal hs-CRP levels, hs-CRP is one of the blood markers most tightly linked to epigenetic age acceleration.

DunedinPACE (Belsky et al., 2022)

DunedinPACE represents a conceptual shift. While the earlier clocks ask "how old does your DNA look?", DunedinPACE asks "how fast are you ageing right now?" It was developed from the Dunedin longitudinal cohort in New Zealand, which tracked 19 physiological parameters across cardiovascular, metabolic, renal, immune, dental, and pulmonary systems from age 26 to 45. By measuring how fast each participant's multi-organ function declined over those two decades, the researchers created a ground-truth "pace of ageing" score, then trained a DNA methylation model to predict it.

A DunedinPACE score of 1.0 represents average ageing speed. A score of 1.2 means the person is ageing 20% faster than average; 0.8 means 20% slower. This framing is intuitively meaningful and arguably more clinically actionable than an age-acceleration figure. The original validation paper, DunedinPACE, a DNA methylation biomarker of the pace of aging, demonstrated strong associations with physical decline and self-rated health. DunedinPACE is also highly responsive to interventions and lifestyle changes, making it attractive for tracking the impact of behaviour change over time.

Blood-Based Biological Age Testing in Australia

Epigenetic clock testing requires a blood draw, DNA extraction, and methylation array analysis. It is not available through Medicare or standard pathology providers. Australians currently have two primary pathways:

TruDiagnostic (US-based, ships to Australia): The most widely used direct-to-consumer epigenetic testing service globally. TruDiagnostic runs the TruAge Complete panel, which reports multiple clock algorithms simultaneously including Horvath, PhenoAge, GrimAge, and DunedinPACE. A blood spot collection kit is posted to the user; samples are returned to the US laboratory. Pricing is typically in the USD $300–500 range depending on the panel selected.

myDNAge (US-based, international availability): Another direct-to-consumer option offering Horvath-based biological age estimation from blood or urine. Fewer clock algorithms are reported than TruDiagnostic. Cost is lower, typically USD $199–299.

Integrative and longevity medicine clinics: Some Australian longevity-focused clinics (particularly in Sydney and Melbourne) are beginning to offer epigenetic age testing as part of extended panels, often bundled with telomere length assessment, advanced lipids, and inflammatory markers. This route provides clinical interpretation but typically at higher total cost.

For context on the broader landscape of private and self-referral blood testing in Australia, see the private blood test in Australia guide.

How Telomere Length Fits In

Telomere length is the other commonly cited measure of biological ageing at the cellular level. Telomeres are the protective caps at chromosome ends that shorten with each cell division. Critically short telomeres trigger cellular senescence or apoptosis. Average telomere length in a blood sample declines with age and is associated with age-related disease risk.

However, the relationship between telomere length and epigenetic clock age is modest, not tight. They appear to capture partially overlapping but distinct aspects of cellular ageing. Telomere length is highly variable between individuals and even between cell types, and telomere measurement has significant technical variability depending on the assay used.

The current evidence suggests epigenetic clocks, particularly GrimAge and DunedinPACE, are more reliable predictors of mortality and disease risk than telomere length alone. Many practitioners now consider epigenetic age the primary ageing biomarker and telomere length a secondary or complementary measure.

Inflammatory and Metabolic Markers That Relate to Epigenetic Age

Epigenetic age acceleration does not exist in isolation. It is tightly correlated with a cluster of blood markers that are available through standard Australian pathology:

Chronic low-grade inflammation: Elevated hs-CRP, interleukin-6, and TNF-alpha are consistently associated with accelerated epigenetic ageing. Chronic inflammation appears both to drive methylation changes and to be partially caused by ageing-related epigenetic dysregulation, a bidirectional relationship.

Insulin resistance and metabolic dysfunction: HOMA-IR, fasting insulin, and HbA1c correlate with epigenetic age acceleration. Metabolic syndrome is associated with a measurable increase in GrimAge and PhenoAge scores independent of chronological age. For reference ranges and interpretation, see the HOMA-IR insulin resistance calculator guide.

DHEA-S: Adrenal androgen status has a notable relationship with epigenetic age. Lower DHEA-S is associated with greater biological age acceleration, and DHEA-S decline tracks with increasing methylation-based age estimates across longitudinal studies. The DHEA-S adrenal reserve marker guide covers how to interpret this in context.

Omega-3 index: Higher omega-3 index (the proportion of EPA+DHA in red blood cell membranes) is associated with slower epigenetic ageing in several studies. It is one of the few nutritional biomarkers with consistent association across multiple clock algorithms.

Homocysteine: Elevated homocysteine is associated with accelerated methylation ageing, likely via its role in the methyl donor pathway. Adequate B12, folate, and B6 support appropriate homocysteine metabolism and are relevant to the broader epigenetic maintenance picture.

Interpreting an Accelerated Biological Age Result

Receiving a result showing biological age older than chronological age (say, a GrimAge acceleration of +5 years) should be contextualised rather than treated as a diagnosis.

Several factors influence the result beyond intrinsic ageing rate:

• Smoking history: DNAm-based smoking surrogates are embedded in GrimAge. Current or former smokers typically show elevated GrimAge even if other health markers are good. The algorithm partly reflects cumulative smoking exposure, not just current physiology.
• Acute illness or recent inflammation: A blood draw during or shortly after a significant inflammatory event (surgery, infection, viral illness) may transiently elevate epigenetic age estimates.
• BMI and metabolic status: Higher adiposity and insulin resistance consistently associate with accelerated epigenetic ageing; improvements in metabolic health produce measurable reductions in clock acceleration over 6–12 months.
• Technical variability: No assay is perfectly reproducible. Within-individual variability between draws is typically ±1–3 years for most clocks. A single elevated result should not be over-interpreted without a baseline or follow-up measurement.

What the Evidence Says About Reducing Epigenetic Age Acceleration

The most encouraging aspect of epigenetic clock research is evidence of bidirectional change: interventions can reduce biological age acceleration, not just slow its progression.

Exercise is the most consistently supported intervention. Aerobic and resistance training both associate with lower epigenetic age, with effect sizes ranging from 1–3 years of age reduction in intervention trials of 8–24 weeks.

Caloric restriction and dietary quality: The CALERIE trial and several Mediterranean diet studies have shown reductions in PhenoAge acceleration with sustained dietary change. The effect is most pronounced with reduction in ultra-processed food intake and improvement in metabolic markers.

Sleep: Chronic short sleep duration (<6 hours) is associated with accelerated epigenetic ageing across multiple clocks. Improving sleep duration and quality shows measurable effects on biological age over months.

Methyl donor nutrients: Given the biochemical role of methylation, adequate folate, B12, choline, and betaine, verified through homocysteine and B12 blood testing, is mechanistically relevant, though intervention studies are less numerous than for exercise.

Stress reduction: Chronic psychological stress and elevated allostatic load are associated with epigenetic age acceleration, particularly via the cortisol–inflammation axis. Mindfulness-based stress reduction programs have shown modest reductions in epigenetic age in small trials.

The research framing is important: these are population-level associations and modest mean effects in intervention trials. Individual responses vary. Epigenetic testing is most useful as a longitudinal tool, measuring change across 12–24 months in response to tracked interventions, rather than as a one-time risk stratification.

Limitations of Current Epigenetic Clock Testing

Several important caveats apply to the current state of the field:

Reference populations: Most epigenetic clocks were developed and validated primarily in North American and European cohorts. Australian-specific reference norms are not established, though global validation studies include diverse populations.

Clinical translation lag: Despite strong epidemiological associations, epigenetic age results are not yet integrated into Australian clinical guidelines, Medicare, or standard specialist frameworks. Results sit outside the conventional diagnostic pathway.

Algorithm proliferation: Dozens of epigenetic clocks now exist, and they do not always agree. A person may show acceleration on one clock and deceleration on another. Composite or multi-clock reporting (as offered by TruDiagnostic) is more informative than any single algorithm.

Causal direction is not fully resolved: Association between epigenetic age acceleration and disease does not fully establish that reducing epigenetic age reduces disease risk. Trials directly testing this are ongoing.

Getting Started With Biological Age Testing in Australia

The most practical pathway for most Australians is direct-to-consumer testing via TruDiagnostic or myDNAge with a blood spot or venous blood draw. For those who prefer clinical oversight, an integrative or functional medicine practitioner can order the test and contextualise results alongside a full metabolic, inflammatory, and hormonal panel.

Regardless of the result, the biomarkers that drive epigenetic age acceleration (fasting insulin, hs-CRP, HOMA-IR, homocysteine, DHEA-S, and omega-3 index) are all available through standard Australian pathology, many without a GP referral. Addressing modifiable contributors to these markers is where the evidence base for intervention is strongest and most actionable. For a practical guide to making sense of a full panel, see how to interpret blood test results.

Biological age testing is not a diagnostic tool in the traditional sense. It is a rate-of-change signal that can inform the urgency and direction of lifestyle and metabolic optimisation, most usefully when measured repeatedly over time rather than interpreted as a single fixed verdict.

This article is for informational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare practitioner before making changes to your health management based on biomarker results.